Namenda
Namenda 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Hepatocellular Carcinoma、Cirrhosis。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
21 项
全球在招研究
5 项
已进入 III/IV 期
10 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Inova Health Care Services
- Ain Shams University
- Bjorn H. Ebdrup
- Chinese PLA General Hospital
- ChenXiaoChun
- Case Comprehensive Cancer Center
- Mclean Hospital
- Massachusetts General Hospital
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
Egypt、丹麦、美国、中国、Russia、英国、Philippines、瑞士、加拿大、India
正在招募患者的 Namenda 研究
"The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients"
II 期招募中EgyptNCT06679387Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
I 期招募中丹麦NCT04789915A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
II 期 / III 期招募中美国NCT06007846Study Safety and Efficacy of Deep Brain Stimulation (DBS) and Cervical Deep Lymphoid-venous Anastomosis (LVA) in Alzheimer's Disease
I 期招募中中国NCT07094438Ozanimod in Patients With Alzheimer's Disease
II 期招募中中国NCT06862960Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)
II 期招募中美国NCT07248228Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression
早期 I 期招募中美国NCT07560878NTS-WBRT in Brain Metastases
II 期招募中美国NCT05013892Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
II 期招募中美国NCT06041789Pattern Separation in Major Depressive Disorder
I 期招募中美国NCT07139834Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
II 期招募中美国NCT06727773Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
III 期招募中RussiaNCT07251023Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
II 期 / III 期招募中英国NCT04302870Monitoring Drug Efficacy in Patients with Alzheimer's Disease
不适用招募中PhilippinesNCT05801380Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
II 期招募中美国NCT07470606The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
II 期招募中美国NCT06789757Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
II 期招募中美国NCT05045950Glutamate Inhibitors in Glioblastoma
I 期 / II 期招募中瑞士NCT05664464Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
III 期招募中美国加拿大NCT03550391Pragmatic Trial of Obsessive-compulsive Disorder
II 期招募中中国NCT04539951Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI
III 期招募中IndiaNCT06275035
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。